GDC-0810 was developed as an oral drug for use as a single agent, or in combination, for treatment of estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2−) breast cancer (4). This evidence concerns the gene ESR1 and breast carcinoma.